But it is safe to say. . . it works. Unlike the "Silver" toothpaste [or thus far, Trump's touted malaria drugs -- sans evidence], it appears clear that Gilead's cndidate is improving outcomes. Here's the bit:
. . . .Gilead's experimental drug for patients with severe Covid-19 infections showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.
The report published in the New England Journal of Medicine tracked 53 people in the U.S., Europe and Canada who needed respiratory support, with about half receiving mechanical ventilation and four on a heart-lung by-pass machine. . . .
All received remdesivir for up to 10 days on a compassionate use basis, a program that allows people to use unapproved medicines when no other treatment options are available. Over 18 days, 68% of the patients improved, with 17 of the 30 patients on mechanical ventilation being able to get off the breathing device. Almost half of the patients studied were ultimately discharged, while 13% died. Mortality was highest among those who were on a ventilator, with 18% of them dying. . . .
The newest data sets on ventilators are worrisome, as they seem to show some severe cases are more likely to die, if put on a ventilator -- all of which might mean that the Gilead drug is more effective than this small study suggests.
Onward, in silence -- on Holy Saturday morning. . . but smiling. Ever smiling. . . . and sadly, Mr. Shkreli will never be up to this:
नमस्ते
No comments:
Post a Comment